Eva Wagner-Drouet

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

Andréas Mackensen, John B.A.G. Haanen, Christian Koenecke et al. · Nature Medicine · 2023 · 218 citations · Full text

Cancer Immunosurveillance, Cldn6-specific Car-t Cells, T Cells +15

GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany

Wolfgang Bethge, Peter Martus, Michael Schmitt et al. · Blood · 2022 · 210 citations · Full text

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

Dietrich W. Beelen, Rudolf Trenschel, Matthias Stelljes et al. · The Lancet Haematology · 2019 · 147 citations · Full text

A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Norbert Schmitz, Lorenz Truemper, Krimo Bouabdallah et al. · Blood · 2020 · 67 citations · Full text

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

Christina Rautenberg, Friedrich Stölzel, Christoph Röllig et al. · Blood Cancer Journal · 2021 · 62 citations · Full text